EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pazopanib Combined With Vincristine and Irinotecan in Relapsed Wilms Tumor: Encouraging Outcomes in a Heavily Pretreated Pediatric Cohort

Maria Debora De Pasquale iD, Alessandro Crocoli iD, Giuseppe Maria Milano iD, Pierluigi Di Paolo, Francesca Diomedi Camassei, Ida Russo iD, Annalisa Serra

Pediatric Blood & Cancer · 2026

DOI: 10.1002/1545-5017.70020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Maria Debora De Pasquale und 6 weiteren Autor:innen. Beteiligte Einrichtung: Oncohematology, Hemopoietic Transplantation, Cellular Therapies and Clinical Trials, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Wilms Tumor, Antineoplastic Combined Chemotherapy Protocols, Kidney Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While Wilms tumor (WT) typically has a favorable prognosis, relapsed cases—especially those with high‐risk histology—remain therapeutically challenging after intensive frontline therapy. The combination of vincristine and irinotecan has demonstrated activity in pediatric solid tumors, and pazopanib, a multi‐targeted tyrosine kinase inhibitor, might enhance treatment efficacy through antiangiogenic mechanisms.

Methods

This report included six children with relapsed WT treated between 2015 and 2022 at Bambino Gesù Children's Hospital, Rome. All patients had received prior multimodal therapy, including six chemotherapeutic agents. The VIPaz regimen (vincristine, irinotecan, pazopanib) was administered as second‐ or third‐line therapy in combination with surgery and/or radiotherapy. Treatment response and toxicity were evaluated.

Results

Five out of six patients (83%) responded to the treatment. Three (50%) achieved complete remission and remained disease‐free at 27, 74, and 76 months post‐treatment. VIPaz was generally well‐tolerated. No Grade >3 toxicities were observed.

Conclusion

VIPaz in combination with surgery and/or radiotherapy demonstrated an acceptable safety profile and durable responses in 50% of heavily pretreated patients with relapsed high‐risk WT. Although limited by small sample size and retrospective design, these findings support further prospective evaluation of pazopanib‐based regimens and biomarker‐driven approaches in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Wilms TumorAntineoplastic Combined Chemotherapy ProtocolsKidney NeoplasmsNeoplasm Recurrence, LocalHumansSulfonamidesIrinotecanPyrimidinesVincristineFemaleIndazolesMaleChild, PreschoolChildInfantPrognosisRetrospective StudiesFollow-Up Studies

Stichwörter der Autor:innen

childrenirinotecanpazopanibrelapsed Wilms tumor

Substanzen

SulfonamidespazopanibIrinotecanPyrimidinesVincristineIndazoles

Autor:innen und Institutionen

  • Oncohematology, Hemopoietic Transplantation, Cellular Therapies and Clinical Trials, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Surgical Oncology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Diagnostic Radiology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Pathology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

ORCID-Profile: Maria Debora De Pasquale, Alessandro Crocoli, Giuseppe Maria Milano, Ida Russo

Förderung

  • Italian Ministry of Health

Zitieren

APA

De Pasquale, M. D., Crocoli, A., Milano, G. M., Paolo, P. D., Camassei, F. D., Russo, I., & Serra, A. (2026). Pazopanib Combined With Vincristine and Irinotecan in Relapsed Wilms Tumor: Encouraging Outcomes in a Heavily Pretreated Pediatric Cohort. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70020

Vancouver

De Pasquale MD, Crocoli A, Milano GM, Paolo PD, Camassei FD, Russo I, et al. Pazopanib Combined With Vincristine and Irinotecan in Relapsed Wilms Tumor: Encouraging Outcomes in a Heavily Pretreated Pediatric Cohort. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70020

BibTeX
@article{DePasquale2026,
  author = {De Pasquale, Maria Debora and Crocoli, Alessandro and Milano, Giuseppe Maria and Paolo, Pierluigi Di and Camassei, Francesca Diomedi and Russo, Ida and Serra, Annalisa},
  title = {Pazopanib Combined With Vincristine and Irinotecan in Relapsed Wilms Tumor: Encouraging Outcomes in a Heavily Pretreated Pediatric Cohort},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  doi = {10.1002/1545-5017.70020}
}
Kostenlos starten →